As of 2026-04-08, the Intrinsic Value of Inhibrx Inc (INBX) is (281.49) USD. This INBX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 62.35 USD, the upside of Inhibrx Inc is -551.50%.
The range of the Intrinsic Value is (923.10) - (171.63) USD
Based on its market price of 62.35 USD and our intrinsic valuation, Inhibrx Inc (INBX) is overvalued by 551.50%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (923.10) - (171.63) | (281.49) | -551.5% |
| DCF (Growth 10y) | (169.96) - (821.49) | (266.21) | -527.0% |
| DCF (EBITDA 5y) | (131.17) - (161.71) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (139.87) - (181.16) | (1,234.50) | -123450.0% |
| Fair Value | -166.34 - -166.34 | -166.34 | -366.79% |
| P/E | (124.82) - (140.52) | (136.07) | -318.2% |
| EV/EBITDA | (94.78) - (91.69) | (97.22) | -255.9% |
| EPV | (179.18) - (259.90) | (219.54) | -452.1% |
| DDM - Stable | (80.33) - (706.69) | (393.51) | -731.1% |
| DDM - Multi | (127.29) - (899.34) | (225.66) | -461.9% |
| Market Cap (mil) | 906.57 |
| Beta | 1.01 |
| Outstanding shares (mil) | 14.54 |
| Enterprise Value (mil) | 882.91 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.32% |
| Cost of Debt | 7.00% |
| WACC | 7.29% |